1AI

16.7%

0.7¢ algorae pharmaceuticals limited

phase II Vs phase I, page-17

First 17 Last

Share
Profile

Follow
pocket-rocket

170 Posts.

8

24/10/17

21:58

Post #: 28163043
Share

Originally posted by whytee ↑

Problem is your table only gives a dose response curve from 0 (Placebo) to 120 (max) for the 18 "identical" patients. It is unlikely to be the case.

It gets more complicated as other variables which might influence response get taken into account such as duration and severity of the illness and dose and baseline response to L-dopa. The usual demographic data such as age and sex of the trial patients will also be included.

Then we have the single primary outcome and 7 secondary outcome measures. While the trial goes for 26 weeks, there might well have been multiple evaluations - in the first trial the patients were examined every 4 weeks. So a wealth of data could be generated which will need to be analysed.

The expectation would be that all of the patients (including the placebo ones) will show an initial improvement in the PDQ-39 Quality of Life scores, but this will decline in the placebo patients over the six months while being sustained in the treated patients. The placebo patients will not show any improvement in objective observed motor performance and may require an increase in medication, whereas the treated patients will show a steady improvement in motor performance over the six months and a reducing dose of medication. The improvement in response will possibly be faster and more complete in those patients with less severe disease to begin with, and a slower but still significant response in the more severely affected patients who initially were on more medication to begin with. Age and sex might not be significant factors when severity is taken into account. If data is available after the 26 weeks it will likely show continued, sustained improvements.

Honestly I am not sure how much effect bigger doses will have over six months. Neurones grow relatively slowly and probably LCT had some good reason to start with a dose of 40 based on their animal testing. But given that some of the implanted cells will probably die, more might be better so a reasonable position would be to guess that 80 will be better than 40 but 120 not much of an improvement over 80.

All just educated guess work on my part, but LCT are "eagerly awaiting the results...", so perhaps that indicates some confidence. I'm betting heavily that the result will be positive in all groups except the placebo patients, but there will be considerable variation in response of the treated patients according to the initial disease severity. The result will be clear however.

Expand

@whytee I really appreciate you took the time to response, given the various typo in my post. Your assumptions are sensible and guesses are very educated (in my view). Thanks again, great comment.

LCT Price at posting: 24.5¢ Sentiment: Hold Disclosure: Held
3 Upvote

0 Great analysis

Reply

Top Stories

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

SLS

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

BUX

Buxton projects new graphite province discovery at WA Narryer play

BCI

BCI reaches close of funding facility for salt-first part of Mardie project

NTI

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

CKA

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

WCN

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

There are more pages in this discussion • 30 more messages in this thread...

First 17 Last

Add 1AI (ASX) to my watchlist

(20min delay)
Last 0.7¢		Change 0.001(16.7%)		Mkt cap ! $11.81M

Open	High	Low	Value	Volume
0.6¢	0.7¢	0.6¢	$746	107.7K

Buyers (Bids)

No.	Vol.	Price($)
17	5265293	0.6¢

Sellers (Offers)

Price($)	Vol.	No.
0.7¢	90900	1

View Market Depth

No.	Vol.	Price($)
17	5265293	0.006
13	5177919	0.005
6	3695009	0.004
2	3100000	0.003
2	1050000	0.002

Price($)	Vol.	No.
0.007	90900	1
0.008	2252112	10
0.009	1828673	9
0.010	4020149	6
0.011	909287	4

Last trade - 16.10pm 04/10/2024 (20 minute delay)

1AI (ASX) Chart

phase II Vs phase I, page-17

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

phase II Vs phase I, page-17

Top Stories

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Week 40 Wrap: China's nonsensical stimmy hype wanes (shocking!); HotCopper's picks; oil & inflation

Solstice Minerals to ramp up drilling campaign at Yarri Gold Project

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

Buxton projects new graphite province discovery at WA Narryer play

BCI reaches close of funding facility for salt-first part of Mardie project

Neurotech knocked back by FDA as agency declares target condition not rare enough for special status

Cokal upgrades infrastructure for BBM ramp-up in Indonesia

White Cliff jumps 24% on 'bonanza grade' copper rock chips at Rae project, Canada

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News